BBIO Stock Forecast & Price Target

BridgeBio Pharma is well-positioned for future growth, with a strong development pipeline targeting rare genetic diseases and oncology. Their recent submission to the FDA and plans for a European Medicines Agency submission for their flagship product, Attruby, indicate potential for early market entry and revenue generation. With potential commercialization of Attruby in 2027 and further expansion into other indications, including hypoparathyroidism, encaleret could contribute significantly to overall company revenues. The recent IP settlement for their other product, Vyndamax, also provides stability for revenues in the mid-2030s, further strengthening BridgeBio's long-term prospects. Overall, our 10-year DCF yields a price objective of $102, reflecting potential for continued growth and achievement of regulatory milestones.

BridgeBio Pharma is faced with significant risks such as delays in obtaining approval for its various candidates, legislative and macro pressures on drug pricing, and difficulties in establishing a productive commercial infrastructure. The strategy to use PRVs as a source of capital may provide near-term relief, but long-term sustainability remains a concern. While the recent positive KOL checks and potential launch of several drugs could bring some near-term upside, the overall negative outlook is based on the company's high valuation and risks associated with its pipeline development.